Home » Stocks » Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc. (TTPH)

Jul 28, 2020 - TTPH was delisted after being acquired by LJPC
Stock Price: $2.20 USD 0.00 (0.00%)
Updated Jul 28, 2020 4:00 AM UTC

Stock Price Chart

Key Info

Market Cap 15.98M
Revenue (ttm) 7.86M
Net Income (ttm) -62.72M
Shares Out 7.26M
EPS (ttm) -13.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 28, 2020
Last Price $2.20
Previous Close $2.20
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 2.18 - 2.27
Day's Volume 0
52-Week Range 0.56 - 8.60

More Stats

Market Cap 15.98M
Enterprise Value n/a
Earnings Date (est) Jul 30, 2020
Ex-Dividend Date n/a
Shares Outstanding 7.26M
Float 5.42M
EPS (basic) -16.86
EPS (diluted) -13.31
FCF / Share -5.82
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 219,037
Short Ratio 0.16
Short % of Float 4.04%
Beta 2.32
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 2.03
PB Ratio 0.63
Revenue 7.86M
Operating Income -60.76M
Net Income -62.72M
Free Cash Flow -54.00M
Net Cash 24.16M
Net Cash / Share 3.33
Gross Margin -226.02%
Operating Margin -773.17%
Profit Margin -798.20%
FCF Margin -687.20%
ROA -51.47%
ROE -138.81%
ROIC -585.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 0
Overweight 0
Hold 1
Underweight 0
Sell 1

Analyst Consensus: Underweight

Price Target

$30.00*
Low
30.0
Current: $2.20
High
30.0
Target: 30.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue7.3818.909.675.1511.699.1010.497.600.19
Revenue Growth-60.98%95.57%87.87%-55.97%28.45%-13.24%37.97%4008.11%-
Gross Profit4.3018.689.675.1511.699.1010.497.600.19
Operating Income-67.53-73.28-116-77.83-83.00-65.77-28.19-14.00-21.43
Net Income-70.09-72.16-115-77.48-83.19-66.74-29.64-15.09-21.56
Shares Outstanding3.072.632.181.841.761.340.830.020.01
Earnings Per Share-22.85-27.48-52.60-42.20-47.20-49.80-35.60-950.80-1,466.80
Operating Cash Flow-63.67-59.63-98.05-63.77-76.71-57.62-24.51-16.66-19.88
Capital Expenditures0.48-0.20-0.77-0.39-0.84-0.19-0.13-0.05-0.07
Free Cash Flow-63.19-59.83-98.82-64.16-77.55-57.81-24.64-16.71-19.94
Cash & Equivalents21.941081371422061211039.2422.62
Total Debt5.0028.29---4.5610.4911.527.75
Net Cash / Debt16.9480.1813714220611792.42-2.2814.87
Assets36.3912314915221512710614.0724.07
Liabilities13.2243.2618.6311.6610.8618.6418.0897.1292.67
Book Value23.1779.6813014020410987.81-83.05-68.60
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Tetraphase Pharmaceuticals, Inc.
Country United States
Employees 67
CEO Larry Edwards

Stock Information

Ticker Symbol TTPH
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: TTPH
IPO Date March 20, 2013

Description

Tetraphase Pharmaceuticals, a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It conducted Phase III clinical trials with Xerava through investigating Gram-negative infections treated with Xerava (IGNITE). The company has completed IGNITE1 and IGNITE4, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of complicated intra-abdominal infections; IGNITE2, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV-to-oral transition therapy for the treatment of complicated urinary tract infections (cUTI); and IGNITE3, a Phase III clinical trial evaluating the safety and efficacy of Xerava with IV administration for the treatment of cUTI. It is also developing TP-271, a synthetic broad-spectrum fluorocycline that is in Phase I clinical trial for respiratory diseases caused by bacterial biothreat pathogens; TP-6076, a synthetic fluorocycline derivative, which is in Phase I clinical trial for multidrug-resistant Gram-negative infections; and TP-2846, a synthetic tetracycline for the treatment of acute myeloid leukemia, which is in pre-clinical stage. Tetraphase Pharmaceuticals, Inc. has a license agreement with Everest Medicines Limited to develop and commercialize Xerava for the treatment of complicated intra-abdominal infections and other indications in mainland China, Taiwan, Hong Kong, Macau, South Korea, and Singapore. The company was founded in 2006 and is headquartered in Watertown, Massachusetts.